title: The impact of pegylated-interferon α-2b on partial and massive hepatectomy model in rats.
abstract: OBJECTIVE
  The impact of pegylated-interferon (PEG-IFN) α-2b on liver regeneration has not yet been elucidated.
  
  
  METHODS
  Rats were divided into the following four groups: 70% hepatectomy (Hx); 70% Hx+PEG-IFN; 90% Hx and 90% Hx+PEG-IFN group (n=6 each). Rats were pretreated with subcutaneous of PEGIFN α-2b (1.5 μg/kg) administration 24 hours before Hx. Samples were taken 24, 48 and 72 hours after Hx and the following parameters were investigated: blood analysis (AST, WBC, PLT); liver weight to body weight ratio (Lw/Bw ratio); survival and PCNA labeling index (LI).
  
  
  RESULTS
  In the 90% Hx model, there was no significant difference between the Hx+PEG-IFN group and the Hx alone group in blood analysis; AST after postoperative 24 hours (2511 vs. 2466 IU/L), WBC (1200 vs. 1290) and PLT (107 vs. 111 x 10⁴/mm³), in Lw/Bw ratio at postoperative 0, 24, 48, 72 hours, respectively (0.38, 0.60, 1.14, 1.69 vs. 0.37, 0.64, 1.12, 1.63), in postoperative survival (40% vs. 45%), and in PCNA LI at postoperative 0, 24, 48, 72 hours, respectively (10.4%, 16.8%, 14.6%, 12.8% vs. 10.0%, 17.1%, 15.6%, 13.7%). In the 70% Hx model, there was no significant difference between the Hx+PEG-IFN group and the Hx alone group for all parameters.
  
  
  CONCLUSIONS
  Our data demonstrated that PEG-IFN α-2b did not affect liver regeneration and the early use of PEG-IFN α-2b would cause no problems after liver transplantation using partial grafts including living donor liver transplantation.
authors: Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.
authors: Hiroki
authors: H
authors: Mori
authors: Mitsuo
authors: M
authors: Shimada
authors: Tohru
authors: T
authors: Ikegami
authors: Tohru
authors: T
authors: Utsunomiya
authors: Satoru
authors: S
authors: Imura
authors: Yuji
authors: Y
authors: Morine
authors: Tetsuya
authors: T
authors: Ikemoto
authors: Jun
authors: J
authors: Hanaoka
authors: Shuichi
authors: S
authors: Iwahashi
authors: Yu
authors: Y
authors: Saito
authors: Michihito
authors: M
authors: Asanoma
authors: Shinichiro
authors: S
authors: Yamada
authors: Hidenori
authors: H
authors: Miyake
mesh_terms: D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D006498:Hepatectomy; D007150:Immunohistochemistry; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000494:pharmacology*; D007958:Leukocyte Count; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D008115:Liver Regeneration / Q000187:drug effects*; D008297:Male; D023421:Models, Animal; D010976:Platelet Count; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000494:pharmacology*; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000009:adverse effects / Q000494:pharmacology; D013997:Time Factors
chemical_list: D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D018809:Proliferating Cell Nuclear Antigen; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D001219:Aspartate Aminotransferases; C417083:peginterferon alfa-2b